BETWEENLicense Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
Exhibit 10.17 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of FEBRUARY 20, 2004, is between Inhibitex, Inc., a Delaware corporation (the "Company"), and DAVID WONNACOTT (the "Executive"). WHEREAS, the Company and the...Executive Employment Agreement • March 3rd, 2004 • Inhibitex Inc
INHIBITEX INCAgreement • January 19th, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
COMMON STOCKUnderwriting Agreement • May 6th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.40 LOAN AGREEMENT DECEMBER 28, 2004 Inhibitex, Inc. Alpharetta, Georgia Ladies and Gentlemen: This letter constitutes the agreement (this "AGREEMENT") between the Borrower and the Lender named below with respect to the Loan described below:...Loan Agreement • March 28th, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • Georgia
COMMON STOCKCommon Stock Purchase Agreement • March 3rd, 2004 • Inhibitex Inc • Minnesota
Exhibit 10.32 [ATHEROGENICS LOGO] SUBLEASE AGREEMENT - Amended and Restated 1. Parties. This sublease agreement (the "Sublease"), entered into this 1st day of January, 2001 is made by and between ATHEROGENICS, INC., a Corporation formed under the laws...Sublease Agreement • March 3rd, 2004 • Inhibitex Inc
SUBLEASE BETWEENSublease • March 3rd, 2004 • Inhibitex Inc
LEASE AGREEMENTLease Agreement • May 6th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • Georgia
Agreement" means this agreement incorporating Schedules 1 (Product Specification), 2 (Services), 3 (Price and Terms of Payment) and Schedule 4 (Inhibitex Patents) as amended or varied from time to time by written agreement of the parties;Confidentiality Agreement • December 10th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
BETWEENExclusive License Agreement • March 3rd, 2004 • Inhibitex Inc • Georgia
COVER PAGEPatent License Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • District of Columbia
Exhibit 10.12 INDEMNITY AGREEMENT This Indemnity Agreement (this "Agreement") is made and entered into as of the _____ day of _______, 2004 by and between INHIBITEX, INC., a Delaware corporation ("Indemnitor") and ___________ ("Indemnitee"). WHEREAS,...Indemnification & Liability • March 3rd, 2004 • Inhibitex Inc • Delaware
AMENDMENT NO. 1 TO THE LICENSE AGREEMENT BETWEEN THE TEXAS A&M UNIVERSITY SYSTEM AND INHIBITEX, INC.License Agreement • March 3rd, 2004 • Inhibitex Inc
RECITALS:Employee Stock Option Agreement • February 14th, 2006 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
WITNESSETHLicense Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • Iowa
RECITALSProduction Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
11,463,415 Shares INHIBITEX, INC. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • April 7th, 2011 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • New York
Inhibitex, Inc.., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative” or “you”) an aggregate of 11,463,415 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,719,512 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares.”
Warrant No. PD Number of SharesWarrant Agreement • March 3rd, 2004 • Inhibitex Inc • Delaware
INHIBITEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • November 24th, 2010 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • New York
Inhibitex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), as follows:
betweenLicence Agreement • May 25th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
Exhibit 10.37 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY AN ASTERISK, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED....Agreement for Services • May 6th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT INHIBITEX, INC. 9005 Westside Parkway Alpharetta, GA 30004 Ladies & Gentlemen: The undersigned, _________________________________(the "Investor"), hereby confirms its agreement with you as follows: 1. This...Securities Purchase Agreement • August 23rd, 2005 • Inhibitex Inc • Biological products, (no disgnostic substances) • New York
AGREEMENT AND PLAN OF MERGER Dated as of January 7, 2012 Among BRISTOL-MYERS SQUIBB COMPANY, INTA ACQUISITION CORPORATION and INHIBITEX, INC.Merger Agreement • January 10th, 2012 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of January 7, 2012, is entered into by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), Inta Acquisition Corporation, a Delaware corporation and a wholly-owned Subsidiary of Parent (“Sub”), and Inhibitex, Inc., a Delaware corporation (the “Company”).
BY AND BETWEENLoan and Security Agreement • March 3rd, 2004 • Inhibitex Inc • Georgia
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 13th, 2011 • Inhibitex, Inc. • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), approved by Board as of December 21, 2010 (the “Effective Date”), is between Inhibitex, Inc., a Delaware corporation (the “Company”), and Geoff Henson (the “Executive”).
DCI MANAGEMENT GROUP LLCPlasma Supply Agreement • March 3rd, 2004 • Inhibitex Inc
RECITALS:Non-Employee Directors Stock Option Agreement • February 14th, 2006 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 10.1 SECOND AMENDMENT TO FOURTH AMENDED AND RESTATED MASTER RIGHTS AGREEMENT This Second Amendment ("Amendment") to the Fourth Amended and Restated Master Rights Agreement ("Master Agreement") dated as of December 19, 2003 among Inhibitex,...Master Rights Agreement • August 16th, 2004 • Inhibitex Inc • Biological products, (no disgnostic substances)
ARTICLE I DEFINITIONSNon-Exclusive Patent License Agreement • March 3rd, 2004 • Inhibitex Inc • California
Exhibit 10.7 FIRST AMENDMENT TO SERIES D CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT This First Amendment ("Amendment") to the Series D Convertible Preferred Stock Purchase Warrants ("Warrants") of Inhibitex, Inc., a Delaware corporation (the...Series D Convertible Preferred Stock Purchase Warrant • March 3rd, 2004 • Inhibitex Inc
EMPLOYEE STOCK OPTION AGREEMENTEmployee Stock Option Agreement • November 9th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
EMPLOYEE STOCK OPTION AGREEMENT, dated as of (this “Agreement”), by and between INHIBITEX, INC., a Delaware corporation (the “Company”), and ___(the “Optionee”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • January 10th, 2012 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 7, 2012, is by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), Inta Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), Inhibitex, Inc., a Delaware corporation (the “Company”) and each of the Persons set forth on Schedule A hereto (each, a “Stockholder”). The Company shall only be a party to this Agreement for purposes of Sections 4.7 through 4.10 and Article V of this Agreement.
PARENT VOTING AGREEMENTParent Voting Agreement • April 13th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS PARENT VOTING AGREEMENT ( this “Agreement”) is entered into as of April 9, 2007, by and between FERMAVIR PHARMACEUTICALS, INC., a Florida corporation (the “Company”), and certain Stockholders of INHIBITEX, INC., a Delaware corporation (“Parent”), whose signatures appear on the signature pages to this Agreement (each a “Stockholder”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined herein).
SECURITY AGREEMENTSecurity Agreement • April 13th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITY AGREEMENT (this “Agreement”), dated as of April 9, 2007, by FERMAVIR PHARMACEUTICALS, INC., a Florida corporation (“FPI”) and FERMAVIR RESEARCH, INC., a Delaware corporation (“FRI”, each of FPI and FRI is referred to herein individually as a “Grantor” and collectively as the “Grantors”), and INHIBITEX, INC., a Delaware corporation (the “Purchaser” or the “Collateral Agent”), as Collateral Agent on behalf of the Holders (as defined herein).
